25 results
Clostridium Dificile Risk by Antibiotic Class

Pooled and study-specific risk estimates of community-associated CDI risk by antibiotic
Clostridium Dificile ... Risk by Antibiotic ... #CDifficile #Infection ... #Pharmacology # ... Clostridium #Table #Comparison
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff ... Primary Clostridium difficile ... infection Episode #Pharmacology ... #Clostridium #CDifficile ... IDSA2017 #Adjunct #Antibiotics
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... if MIC<0.12 ug/ml ... Enteric #Bacterial #IDSA ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... 100 cells/mm3 g/mL ... Penicilliosis #IDSA ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... for Preventing ... HumanPapillomavirus #IDSA ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
IDSA Recommendations ... for Preventing ... Trypanosomiasis #IDSA ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
IDSA Recommendations ... for Preventing ... #Encephalitis #IDSA ... #opportunistic ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... suspension 4–6 mL ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... Castleman’s Disease (MCD ... KaposiSarcoma #Castlemans #IDSA ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
IDSA Recommendations ... Leishmaniasis #Prevention ... Treatment #management #opportunistic ... infections #HIVAIDS #pharmacology